Alaunos Therapeutics Inc (TCRT NASDAQ) stock market data APIs
$5.0489
-0.11(-2.2%)
as of July 3, 2025
Try our APIs with
free plan!
Alaunos Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Prev. Close
5.0489
Open
4.9375
High
4.9879
Low
4.7539
52 wk Range
1.3137-6.992
Market Cap
9 891 K
Shares Outstanding
1 640 K
Revenue
11 000
EPS
-0.6701
Beta
-1.089
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alaunos Therapeutics Inc data using free add-ons & libraries
Get Alaunos Therapeutics Inc Fundamental Data
Alaunos Therapeutics Inc Fundamental data includes:
- Net Revenue: 11 000
- EBITDA: -4 161 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alaunos Therapeutics Inc News
New
Alaunos Therapeutics completes $850,000 private placement of preferred stock
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) announced that it entered into a Subscription Agreement with certain purchasers for a private placement of Series A-2 Convertible Preferred Stock. The agreemen...
Alaunos Therapeutics stock slides on $2M equity offering
* Alaunos Therapeutics (NASDAQ:TCRT [https://seekingalpha.com/symbol/TCRT]) shares fell over 14% premarket on Monday after the company launched an equity offering [https://seekingalpha.com/pr/201439...
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging...
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients h...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
